43 results on '"Beligaswatte A"'
Search Results
2. How comparable are patient outcomes in the 'real-world' with populations studied in pivotal AML trials?
3. High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
4. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
5. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
6. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
7. High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
8. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
9. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
10. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
11. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
12. Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: a cohort study of two different approaches
13. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
14. An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia
15. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
16. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
17. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
18. An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia
19. Comparing the Kinetics of Donor Chimerism Following Myeloablative and Reduced Intensity Conditioning Regimens for Allogenic Haematopoietic Stem Cell Transplant
20. 309 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
21. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
22. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
23. Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis
24. 402 - Comparing the Kinetics of Donor Chimerism Following Myeloablative and Reduced Intensity Conditioning Regimens for Allogenic Haematopoietic Stem Cell Transplant
25. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
26. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness
27. High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?
28. High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?
29. The Australian Experience with Relapsed Acute Myeloid Leukaemia Post Allogeneic Haematopoietic Stem Cell Transplantation Yields a Simple Prognostic Index for Survival after Relapse
30. The Australian Experience with Relapsed Acute Myeloid Leukaemia Post Allogeneic Haematopoietic Stem Cell Transplantation Yields a Simple Prognostic Index for Survival after Relapse
31. High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation
32. The Mean Fluorescence Intensities of Anti-HLA Antibodies Detected Using Micro-Bead Flow Cytometry Predict the Risk of Platelet Transfusion Refractoriness.
33. High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation
34. A case of hereditary spastic paraplegia with demyelinating polyneuropathy
35. A case of hereditary spastic paraplegia with demyelinating polyneuropathy
36. Comparing the Kinetics of Donor Chimerism Following Myeloablative and Reduced Intensity Conditioning Regimens for Allogenic Haematopoietic Stem Cell Transplant
37. Urinary schistosomiasis acquired in Mali, West Africa. I. Case report of Schistosoma haematobium infection in a Sri Lankan with a note on the parasitic life cycle and the risk of local transmission
38. Urinary schistosomiasis acquired in Mali, West Africa. II. Investigation of returnees exposed to risk environment
39. Liver injuries
40. Urinary tract injuries
41. Carcinoma involving the oesophagus: an analysis of 61 patients treated in a general surgical unit
42. Transitional cell carcinoma of the ureter
43. A case of hereditary spastic paraplegia with demyelinating polyneuropathy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.